All News
Orthotics in Rheumatoid Arthritis
Orthotics are cost-effective, externally applied devices designed to stabilize the joints and provide a conservative measure to alleviate joint pain and improve function. Options include therapeutic shoes, shoe inserts, hand splints/braces, wrist support and finger splints. This article reviews some of the indications on the use of orthotics in patients with RA.
Read Article
Overweight & obesity increase risk of Chr. Inflammatory Dz (CIDs). TriNetX EHR study of >3.1 million persons shows risk of any CID=28.5% in overweight/obese vs. 17.6% in controls (HR 1.52). Overweight/obesity posed a > risk of 4 CIDs in females & also >risk for 7 CIDs in Whites… https://t.co/U5ydFGolIY https://t.co/b3Jpl27wLf
Dr. John Cush RheumNow ( View Tweet)
Recent Excess Mortality in Young Adults
JAMA has published a University of Minnesota cross-sectional study showing early adult (ages 25-44) mortality in the U.S. has risen substantially between 2011 to 2019 and 2020 to 2023. The largest portion of 2023 excess mortality was… https://t.co/0LIoMqPkDj https://t.co/Ta5DU6aWfs
Dr. John Cush RheumNow ( View Tweet)
Blood Flow Restriction to Reduce Pain in Knee OA
A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed.
https://t.co/IF1tkT5yvC https://t.co/0zQn8oBjeG
Dr. John Cush RheumNow ( View Tweet)
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/Go5T9pN6wH https://t.co/CIXai9OhZd
Dr. John Cush RheumNow ( View Tweet)
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush RheumNow ( View Tweet)
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive done it) from the Rheumatology Research Foundation, FORWARD and the National Databank folks. We need to know more here; especially from you1 Link:… https://t.co/0KYbgqvceq https://t.co/JeO8hV0luB
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush RheumNow ( View Tweet)
Infectious Sacroiliitis
A large Chinese cohort study of patients with infectious sacroiliitis (SI) suggests that CT-guided biopsy of the sacroiliac joint is necessary to properly identify the infectious pathogen leading to SI.
https://t.co/GYI8iz0rOS https://t.co/3wQR47Wd4g
Dr. John Cush RheumNow ( View Tweet)
Orthotics in Rheumatoid Arthritis
RA is a chronic inflammatory disease affecting synovial joints, often in the hands and feet. Due to its progressive inflammatory nature, RA can lead to impairment of function, reduced quality of life, significant joint pain, disability, and… https://t.co/Tqf5YsSFX3 https://t.co/imnPyNXXkq
Dr. John Cush RheumNow ( View Tweet)
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/LPFFDIeJPA https://t.co/PlTD0fOR2E
Dr. John Cush RheumNow ( View Tweet)
SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4
Dr. John Cush RheumNow ( View Tweet)
NIH study of MSK disease burden finds research on neck pain as most underfunded (0.83%) followed by LBP (13.9%), OA (35.1%) & RA (66.3%) - NIAMS is low compared to other institutes. In USA, MSK dz affect 1 in 3 people, approximately 127.4 million individuals.… https://t.co/MqU9TsY6GR https://t.co/rRvUYc2yee
Dr. John Cush RheumNow ( View Tweet)
German database shows since 2010, work participation has improved for rheum pts, reflected in higher employment, reduced absenteeism and less disability retirement. However, patients have not reached population employment rates. https://t.co/B8VKBgGNGe https://t.co/OOMNym3XrR
Dr. John Cush RheumNow ( View Tweet)
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/n4V0XfMYbA https://t.co/zJ5WVjdfYe
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - An Undiagnosed Autoinflammatory Patient
Autoinflammatory or Still's disease - does this matter?
Features Dr. Jack Cush. QD Clinics - lessons from the clinic
Sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/UimGBUZMeO https://t.co/fkAg9gK0Im
Links:
Dr. John Cush RheumNow ( View Tweet)
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N
Dr. John Cush RheumNow ( View Tweet)
Palmar fasciitis & polyarthritis syndrome (PFPAS). JAMA case 50yoM w/ progressive hand swelling, stiffness, thickening, erythema, hepato-splenomegaly. Skin Bx dermal fibrous tissue. WBC 152k, LDH 889, lead to CML dx made by BM Fx (myeloid-erythroid ratio 21 w/ myeloblasts). +… https://t.co/xtHbzAioss https://t.co/RfMrfntFtb
Dr. John Cush RheumNow ( View Tweet)
“Nothing in all the world is more dangerous than sincere ignorance and conscientious stupidity.”
- Martin Luther King
(Isnt that when someone says “I don’t know and I don’t care”) https://t.co/ZDwyyhX9XT
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2
Dr. John Cush RheumNow ( View Tweet)
